Chlorzoxazone as a single sample probe of hepatis CYP2E1 activity in humans

被引:27
作者
Bachmann, K [1 ]
Sarver, JG [1 ]
机构
[1] UNIV TOLEDO,CTR DRUG DESIGN & DEV,TOLEDO,OH 43606
关键词
chlorzoxazone; clearance; single sample clearance; CYP2E1;
D O I
10.1159/000139381
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this investigation was to determine whether the oral clearance (CL) of chlorzoxazone could be estimated accurately from a single plasma chlorzoxazone measurement. In 6 healthy male subjects the mean clearance estimate (CL(est)) from a single 6-hour postdose measurement of plasma chlorzoxazone was within 6% of the actual mean CL calculated conventionally from the area under the plasma concentration versus time curve (AUG). After a second dose of chlorzoxazone administered I week later, the 6-hour mean CL(est) was within approximately 10% of the value from the previous week and within 15% of the value of CL from the previous week, No significant differences occurred between these three clearances, suggesting that for purposes of phenotyping CYP2E1 activity in humans with chlorzoxazone, a single-dose, single-sample procedure may suffice.
引用
收藏
页码:169 / 177
页数:9
相关论文
共 20 条
[1]   USE OF SINGLE SAMPLE CLEARANCE ESTIMATES OF CYTOCHROME-P450 SUBSTRATES TO CHARACTERIZE HUMAN HEPATIC CYP STATUS INVIVO [J].
BACHMANN, KA ;
JAUREGUI, L .
XENOBIOTICA, 1993, 23 (03) :307-315
[2]   A MINIMAX APPROACH TO THE SINGLE-POINT METHOD OF DRUG DOSING [J].
BAHN, MM ;
LANDAW, EM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (03) :255-269
[3]   THE PROCARCINOGEN HYPOTHESIS FOR BLADDER-CANCER - ACTIVITIES OF INDIVIDUAL-DRUG METABOLIZING ENZYMES AS RISK-FACTORS [J].
BRANCH, RA ;
CHERN, HD ;
ADEDOYIN, A ;
ROMKESSPARKS, M ;
LESNICK, TG ;
PERSAD, R ;
WILKINSON, GR ;
FLEMING, CM ;
DICKINSON, AJ ;
SIBLEY, G ;
SMITH, P .
PHARMACOGENETICS, 1995, 5 :S97-S102
[4]   BOTH CYTOCHROMES P450 2E1 AND 1A1 ARE INVOLVED IN THE METABOLISM OF CHLORZOXAZONE [J].
CARRIERE, V ;
GOASDUFF, T ;
RATANASAVANH, D ;
MOREL, F ;
GAUTIER, JC ;
GUILLOUZO, A ;
BEAUNE, P ;
BERTHOU, F .
CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (06) :852-857
[5]   A SIMPLE METHOD FOR DETERMINATION OF ANTIPYRINE CLEARANCE [J].
DOSSING, M ;
POULSEN, HE ;
ANDREASEN, PB ;
TYGSTRUP, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (03) :392-396
[6]  
DOSSING M, 1983, BR J CLIN PAHRM, V15, P321
[7]  
Gibaldi M, 1982, PHARMACOKINETICS, P433
[8]   ASSESSMENT OF CYTOCHROME P4502E1 INDUCTION IN ALCOHOLIC PATIENTS BY CHLORZOXAZONE PHARMACOKINETICS [J].
GIRRE, C ;
LUCAS, D ;
HISPARD, E ;
MENEZ, C ;
DALLY, S ;
MENEZ, JF .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (09) :1503-1508
[9]   CYTOCHROME P4502E1 (CYP2E1) GENETIC-POLYMORPHISM IN A CASE-CONTROL STUDY OF GASTRIC-CANCER AND LIVER-DISEASE [J].
KATO, S ;
ONDA, M ;
MATSUKURA, N ;
TOKUNAGA, A ;
TAJIRI, T ;
KIM, DY ;
TSURUTA, H ;
MATSUDA, N ;
YAMASHITA, K ;
SHIELDS, PG .
PHARMACOGENETICS, 1995, 5 :S141-S144
[10]   SINGLE-DOSE DISULFIRAM INHIBITION OF CHLORZOXAZONE METABOLISM - A CLINICAL PROBE FOR P450-2E1 [J].
KHARASCH, ED ;
THUMMEL, KE ;
MHYRE, J ;
LILLIBRIDGE, JH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :643-650